Neurogene
NGNE
40 hedge funds and large institutions have $314M invested in Neurogene in 2017 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 6 closing their positions.
123% more call options, than puts
Call options by funds: $256K | Put options by funds: $115K
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
3% more funds holding
Funds holding: 39 → 40 (+1)
8% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 12
0.15% less ownership
Funds ownership: 4.92% → 4.77% (-0.15%)
18% less capital invested
Capital invested by funds: $384M → $314M (-$70.2M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Ascend Capital
Orinda,
California
|
+$3.07M |
| 2 |
UONDDL
University of Notre Dame du Lac
South Bend,
Indiana
|
+$2.45M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.88M |
| 4 |
NC
Nexthera Capital
New York
|
+$1.3M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$11.3M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$5.05M |
| 3 |
BlackRock
New York
|
-$3.27M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.42M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$430K |
NGNE Hedge Fund Activity: Q2 2017 in Review
40 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q2 2017, worth a combined $314M — down 18% from $384M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new NGNE positions and 6 closed out — a net gain of 1 holder — while 13 added to existing stakes and 12 trimmed.
The largest buyer was Ascend Capital, opening a new position worth an estimated $3.07M. The largest seller was RA Capital Management, cutting an estimated $11.3M.
- 40 institutional investors held Neurogene (NGNE) as of Q2 2017, up from 39 in Q1 2017.
- Funds reported $314M of Neurogene stock for Q2 2017, down 18% quarter-over-quarter.
- 7 funds opened new Neurogene positions in Q2 2017 and 6 closed out, a net change of +1 holder.
- The largest Neurogene buyer in Q2 2017 was Ascend Capital, an estimated $3.07M added.
- The largest Neurogene seller in Q2 2017 was RA Capital Management, an estimated $11.3M sold.
Based on aggregated 13F filings for Q2 2017.